Precision Antibacterial Agents: Novel Therapies with Defined Mechanism of Action for Top Priority Bacterial Pathogens

We look for partners interested in:
- To develop new antibacterial agents against deadly pathogens (A. baumannii, P. aeruginosa and Enterobacteriaceae, in particular by employing combined therapies able to inhibit beta-lactamase enzymes.
- To explore new bacterial niches
- To identify the mechanism of action of novel drugs by computational studies.

We offer in-house library of beta-lactamase inhibitors:
- Very stable compounds, able to restore carbapenem activity [1,2]

- Combined therapies [1,2,3]

- Smart mechanism of action; validation by proteomics and ample in-silico studies [1,2]

- Active against difficult to treat pathogens expressing class D carbapenemases [1] and AmpC enzymes (chromosomal) [2]

- Active compounds against unexplored bacterial targets [4]

We offer extensive experience in:

- Drug design, mainly aimed at the treatment of infectious diseases (metalo- and serine-beta-lactamases, essential bacterial enzymes)

- Computational tools (molecular modeling, MD, QM/MM) and proteomics.

- Analyzing the Induced-fit plasticity of a large diversity of targets [5,6,7]

[1] J. Med. Chem. 2020, 63, 3737 https://dx.doi.org/10.1021/acs.jmedchem.0c00127

[2] J. Med. Chem. 2021, 64, 6310 https://doi.org/10.1021/acs.jmedchem.1c00369

[3] J. Med. Chem. 2020, 63, 1859 https://doi.org/10.1021/acs.jmedchem.9b01279

[4] Eur. J. Med. Chem. 2022, 232, 114206 https://doi.org/10.1016/j.ejmech.2022.114206

[5] Adv. Therap. 2021, 4, 2000246 https://doi.org/10.1002/adtp.202000246

[6] Front. Microbiol. 2021, 12, 721826 https://doi.org/10.3389/fmicb.2021.721826

[7] Expo. Health 2022, online https://doi.org/10.1007/s12403-022-00513-0